Hello, Guest!
  • Monday, April 29, 2024

Tim Braswell Named Chief People Officer of Spire Global

Tim Braswell, a 25-year human resources professional, has joined Spire Global (NYSE: SPIR) as chief people officer.

He will be responsible for Spire’s HR functions supporting 375 workers across the globe and spanning recruitment, talent development, health and wellness and employee systems, the space data provider said Tuesday.

Braswell previously held an eight-year career at financial services and insurance company MetLife

The newly appointed chief people officer led HR functions for global finance, risk management, internal audit, compliance and legal affairs leaders in his most recent role at MetLife (NYSE: MET).

His industry experience also includes HR leadership positions at Johnson & Johnson (NYSE: JNJ), Hughes Network Systems and Merck (NYSE: MRK).

Vienna, Virginia-based Spire, which went public in mid-August last year upon completion of the company’s merger with NavSight Holdings, offers space-based data products and analytics services.

Video of the Day

Related Articles

Merck Secures $1.2B CARES Act funds for Antiviral Therapy Contract Awards

Merck Secures $1.2B CARES Act funds for Antiviral Therapy

Army Contracting Command has awarded Merck (NYSE: MRK) a one-year, $1.2 billion contract to deliver nearly 1.7 million courses of molnupiravir, an investigational oral antiviral agent intended to support the treatment of COVID-19 patients. The Department of Defense said Wednesday the full contract amount was obligated on the firm-fixed-price contract using Coronavirus Aid, Relief and

White House Backs Merck-J&J Vaccine Manufacturing Collaboration News

White House Backs Merck-J&J Vaccine Manufacturing Collaboration

The Biden administration is supporting collaboration between Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) to produce more COVID-19 vaccine doses through the Defense Production Act. At the White House’s request, the Department of Health and Human Services has earmarked $105 million in initial funds to help Merck (NYSE: MRK) expand company facilities in

Merck to Receive $356M US Gov’t Funds for COVID-19 Drug Manufacturing, Supply Contract Awards

Merck to Receive $356M US Gov’t Funds for COVID-19 Drug Manufacturing, Supply

Merck (NYSE: MRK) has reached a $356M deal with the departments of Defense and Health and Human Services to further develop and seek regulatory approval MK-7110, the biopharmaceutical firm's investigational drug for hospitalized COVID-19 patients.